ArticleJournal of inflammation research2025
Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatohepatitis (MASH) remains a major clinical challenge due to the lack of effective diagnostic biomarkers and therapeutic targets. Identifying and validating key lipid metabolism-related genes may offer novel strategies for the early diagnosis and targeted treatment of MASH. Methods: In this study, differentially expressed genes (DEGs) were identified from public databases using integrated bioinformatics approaches. Weighted gene co-expression network analysis (WGCNA) and multiple machine learning algorithms were employed to screen for hub genes closely associated with MASH. The expression levels and diagnostic potential of the candidate genes GPD1 and CEBPD were systematically evaluated through nomogram construction, immune infiltration analysis, and both in vivo and in vitro experiments. Their biological functions were further validated at the cellular level. Results: The results revealed a strong association between lipid metabolism dysregulation and alterations in immune cell composition in MASH. GPD1 was significantly upregulated and CEBPD was downregulated in both the MASH animal and cell models, and both genes showed good diagnostic value. Functional experiments demonstrated that knockdown of GPD1 in HepG2 cells significantly reduced lipid accumulation, inflammatory responses, and expression of fibrosis-related markers. Similarly, overexpression of CEBPD also inhibited these pathological processes, indicating that both GPD1 and CEBPD play critical roles in MASH progression. Conclusion: This study highlights the importance of GPD1 and CEBPD as potential diagnostic biomarkers and therapeutic targets for MASH, providing a theoretical and experimental foundation for improving early diagnostic strategies and developing interventions targeting inflammation and lipid metabolism dysregulation in metabolic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.